Dermavir

Dermavir

Created using Figma
We are a privately held clinical-stage biotechnology company focusing on the development and commercialization of a revolutionary new immune therapy platform for the treatment of chronic viral infections, cancer and allergy. Our technology is designed to boost specific immune response in order to modify or control presently incurable diseases.

Our proprietary Vaccine Platform includes a given disease’s antigen specific plasmid DNA (pDNA), a nanomedicine formulation which encapsulates the pDNA to make it closely resemble a virus (we call this combination a nanoparticle), a topical (through the skin) administration device we call DermaPrep which delivers the vaccine via dendritic cell to lymph nodes of the immune system, and a software product which allows us to design antigen specific pDNA and closely match it to a patient’s genetic and HLA profile.

The combination of these technologies supports the rapid and cost-effective development of original biologic vaccine products.
Mar 30, 2018
May 15, 2018
100% completed
Raised funds - no Data
past
Token Details
Ticker
DER
Accepted Currencies
ETH
Company Details
Registered Country
United States
Additional Details
KYC
Yes
Categories
Platform, Health

About Dermavir

Genetic Immunity is a US clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of therapeutic vaccines ("Immune Therapies") for the treatment of chronic viral infections (HIV, HPV), cancer and allergies. Our Immune Therapies are designed to intensify and boost specific immune response to modify or control these presently incurable diseases. We believe our products will allow people to live better, healthier and longer lives.

Our proprietary immunotherapy platform is composed of an pDNA (plasmid DNA) expressing multiple disease specific antigens, a nanomedicine formulation encapsulating the pDNA and a topical administration device which targets the formulation transdermally to dendritic (Langerhans) cells of the skin. Our platform technologies support the rapid and cost-effective development of novel biologic products for several indications and provides tools for the selection of an optimal, patient specific treatment regimen.

Our Lead Product Candidate, a therapeutic vaccine for the treatment of HIV is effective in boosting immune response to kill HIV-infected cells. Our preclinical, Phase I, Phase I/II and Phase II trials have demonstrated HIV-specific T-cells immune response and boosting, and the killing of HIV-infected cells. DermaVir has an excellent safety profile. Our goal is to provide DermaVir as a co-treatment option to antiretroviral therapy (ART), and, upon the completion of an additional clinical trial, to demonstrate efficacy in ART resistant patients, thereby opening a safe, effective new treatment paradigm.

In addition to HIV we also work on an extensive pipeline including therapeutic treatments for cancer, the human papillomavirus, MAGE, allergies and more.

Please see our pipeline of virus-associated cancers and warts in discovery phase section of the website.

Dermavir Team

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

Viktor Rozsnyay
Chief Executive Officer
unverified
Peter Boros
Chief Operations Officer
unverified

Advisors

Verified 0%

Attention. There is a risk that unverified members are not actually members of the team

22 ICOs

$73 692 257

Richard Kastelein
Advisor
unverified

4 ICO

$22 500 000

Feroz Sanaulla
Advisor
unverified

85 ICOs

$204 733 589

Simon Cocking
Advisor
unverified

127 ICOs

$668 469 232

Ian Scarffe
Advisor
unverified

Dermavir Last News

  • Due to potential time differences in information updates, please verify the accuracy of each ICO project through its official website or other official communication channels.
  • This information is not intended as a recommendation or suggestion for ICO investment. Please conduct thorough research on the relevant information and make your own informed decision regarding ICO participation.
  • If you identify any issues or errors in this content, or if you wish to submit your own ICO project for listing, please contact us via email at info@icoholder.com.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.